Andres Isaias is a biotechnology executive based in Miami, Florida, known for leading Restem Group, Inc. as chief executive officer since 2018. Under his direction, the company has advanced a portfolio of cellular therapeutics designed for patients facing limited or insufficient treatment options. With a focus on safety, innovation, and accessibility, he helps drive programs targeting autoimmune and inflammatory diseases, as well as broader applications in regenerative and age-related care.
In his role, Mr. Isaias oversees corporate strategy and daily operations while helping position the company for long-term scientific and commercial success. He is involved in efforts related to FDA approval processes for therapies using modified umbilical cord lining progenitor cells, and he supports the continued advancement of treatments across multiple indications. Restem’s pipeline includes Restem-L for facioscapulohumeral muscular dystrophy, as well as secretomes for orthopedic use, exosomes for skin and hair care, and cellular therapies under development for addiction, cardiovascular conditions, and disorders affecting the central nervous system.
Before joining Restem Group, Andres Isaias worked extensively with children living with autism, an experience that informs his commitment to improving patients’ quality of life through emerging medical solutions. He earned degrees in business and engineering from Tulane University in New Orleans. Active in the biotechnology community, he has represented Restem at leading conferences such as the BIO International Convention and the Jones Trading Technology and Healthcare Conference, while also maintaining involvement with organizations including Biocom California and the California Life Sciences Organization.
